Caribou Biosciences, Inc. - Common Stock (CRBU)

1.7200
+0.0400 (2.38%)

Caribou Biosciences Inc is a biotechnology company focused on developing transformative cellular therapies using its proprietary CRISPR genome-editing technology

The company leverages its innovative platform to create engineered immune cells for the treatment of various cancers and other serious diseases. By harnessing the power of CRISPR, Caribou aims to enhance the precision and effectiveness of therapies, ultimately improving patient outcomes and advancing the field of genetic medicine.

SummaryNewsPress ReleasesChartHistoricalFAQ
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga.com
Via Benzinga · November 26, 2024
Expert Ratings For Caribou Biosciencesbenzinga.com
Via Benzinga · September 3, 2024
Caribou Biosciences Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)benzinga.com
Via Benzinga · August 14, 2024
Evaluating Caribou Biosciences: Insights From 4 Financial Analystsbenzinga.com
Via Benzinga · July 17, 2024
Cracking The Code: Understanding Analyst Reviews For Caribou Biosciencesbenzinga.com
Via Benzinga · June 4, 2024
12 Health Care Stocks Moving In Monday's Intraday Sessionbenzinga.com
Via Benzinga · June 3, 2024
Expert Ratings For Caribou Biosciencesbenzinga.com
Via Benzinga · May 16, 2024
Attention Biotech Investors - Stocks To Watchbenzinga.com
RBC's Chris McCarthy discusses biotech investor sentiment at the RBC Global Healthcare Conference. Focused on upcoming binary catalysts, McCarthy highlights Agios Pharmaceuticals, Caribou Biosciences, and Corbus Pharmaceuticals with key 2024 data readouts and trials.
Via Benzinga · May 16, 2024
3 Underappreciated Stocks That Could 10x in 10 Yearsinvestorplace.com
10x stocks are the holy grail of capital investing. So, here are three companies that have the potential to cross that line.
Via InvestorPlace · May 12, 2024
CRBU Stock Earnings: Caribou Biosciences Misses EPS, Misses Revenue for Q1 2024investorplace.com
CRBU stock results show that Caribou Biosciences missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via InvestorPlace · May 7, 2024
Kura Sushi Posts Upbeat Sales, Joins Caribou Biosciences, Krispy Kreme And Other Big Stocks Moving Higher In Friday's Pre-Market Sessionbenzinga.com
U.S. stock futures were higher this morning, with the Dow futures gaining by around 100 points on Friday.
Via Benzinga · April 5, 2024
Investor Sentiment Improves Following Inflation Data, Dow Jumps Over 200 Pointsbenzinga.com
The CNN Money Fear and Greed index showed some improvement in the overall market sentiment, but the index remained in the "Greed" zone on Tuesday.
Via Benzinga · March 13, 2024
Why Caribou Biosciences Stock Is Crashing Todayfool.com
Investors didn't like the clinical-stage biotech's Q4 update for one key reason.
Via The Motley Fool · March 12, 2024
Gold Down Over 1%; ClearOne Shares Spike Higherbenzinga.com
U.S. stocks traded higher toward the end of trading, with the S&P 500 index gaining over 1% on Tuesday. The Dow traded up 0.74% to 39,057.10 while the NASDAQ rose 1.41% to 16,245.83. The S&P 500 also rose, gaining, 1.10% to 5,174.28.
Via Benzinga · March 12, 2024
Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Sessionbenzinga.com
Shares of Asana, Inc. (NYSEASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance.
Via Benzinga · March 12, 2024
12 Health Care Stocks Moving In Tuesday's Intraday Sessionbenzinga.com
Via Benzinga · March 12, 2024
It's A Bull Market But Harder To Pick Small Cap Biotech Winners Because Of Volatilitytalkmarkets.com
Biotech is in a bull market aș measured by 2023 trends with a double testing of lows on 11/23.
Via Talk Markets · March 11, 2024
Missed Out on CRISPR Therapeutics? My Best Gene-Editing Stock to Buy and Holdfool.com
Buy this stock if you're daring, but avoid it for now if you aren't.
Via The Motley Fool · February 26, 2024
2 Risky Gene-Editing Stocks to Buy in the New Bull Market if You Darefool.com
It's less scary to take on risky investments when the market is rising.
Via The Motley Fool · February 12, 2024
3 Biotech Stocks You Can Buy and Hold for the Next Decadefool.com
These companies are still in the early innings of their growth potential.
Via The Motley Fool · January 15, 2024
3 Gene-Editing Stocks With the Potential to Mint Millionairesinvestorplace.com
Gene editing stocks are very likely to see a spike in demand over the coming weeks in the wake of FDA approval of CRISPR.
Via InvestorPlace · December 13, 2023
Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapyinvestorplace.com
These three gene therapy stocks should get huge boosts over the long term from the use of gene editing techniques to treat diseases.
Via InvestorPlace · December 7, 2023
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.fool.com
The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach.
Via The Motley Fool · December 4, 2023
Ross Stores Reports Strong Earnings, Joins Buckle, Twist Bioscience And Other Big Stocks Moving Higher On Fridaybenzinga.com
U.S. stocks traded mostly lower, with the Dow Jones falling over 20 points on Friday.
Via Benzinga · November 17, 2023
Why Bluegreen Vacations Shares Are Trading Higher By Around 105%? Here Are Other Stocks Moving In Monday's Mid-Day Sessionbenzinga.com
Gainers Carbon Revolution Public Limited (NASDAQCREV) shares jumped 396.2% to $145.49 after gaining 100% on Friday. The company’s stock began trading on Friday following merger with Twin Ridge Capital Acquisition Corp.
Via Benzinga · November 6, 2023